These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33008266)

  • 1. Inflammatory cytokines, oxidative and antioxidative stress levels in patients with diabetic macular edema and hyperreflective spots.
    Sabaner MC; Akdogan M; Doğan M; Oral AY; Duman R; Koca T; Bozkurt E
    Eur J Ophthalmol; 2021 Sep; 31(5):2535-2545. PubMed ID: 33008266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in choroidal thickness after anti-vascular endothelial growth factor treatment of diabetic macular edema, real-life data, 2-year results.
    Savur F; Kaldırım H; Atalay K; Korkmaz Ş
    Cutan Ocul Toxicol; 2021 Dec; 40(4):326-331. PubMed ID: 34275395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic Macular Edema With and Without Subfoveal Neuroretinal Detachment: Two Different Morphologic and Functional Entities.
    Vujosevic S; Torresin T; Berton M; Bini S; Convento E; Midena E
    Am J Ophthalmol; 2017 Sep; 181():149-155. PubMed ID: 28687219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavior of hyperreflective spots noted on optical coherence tomography following intravitreal therapy in diabetic macular edema: A systematic review and meta-analysis.
    Ganne P; Krishnappa NC; Karthikeyan SK; Raman R
    Indian J Ophthalmol; 2021 Nov; 69(11):3208-3217. PubMed ID: 34708775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers.
    Bonfiglio V; Reibaldi M; Pizzo A; Russo A; Macchi I; Faro G; Avitabile T; Longo A
    Acta Ophthalmol; 2019 Jun; 97(4):e540-e544. PubMed ID: 30318792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic contribution of inflammatory mediators to the severity of diabetic and uveitic macular edema.
    Figueras-Roca M; Matas J; Llorens V; Sala-Puigdollers A; Navarro M; Zarranz-Ventura J; Adán A; Molins B
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2695-2705. PubMed ID: 33710470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HYPERREFLECTIVE RETINAL SPOTS AND VISUAL FUNCTION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN CENTER-INVOLVING DIABETIC MACULAR EDEMA.
    Vujosevic S; Berton M; Bini S; Casciano M; Cavarzeran F; Midena E
    Retina; 2016 Jul; 36(7):1298-308. PubMed ID: 26689274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracystic hyperreflective material in centre-involving diabetic macular oedema.
    Venkatesh R; Sangai S; Reddy NG; Sridharan A; Pereira A; Aseem A; Gadde SGK; Yadav NK; Chhablani J
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2533-2544. PubMed ID: 33710472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of aqueous cytokines in patients with different patterns of diabetic macular edema based on optical coherence tomography.
    Bandyopadhyay S; Bandyopadhyay SK; Saha M; Sinha A
    Int Ophthalmol; 2018 Feb; 38(1):241-249. PubMed ID: 28160192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
    Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
    Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
    [No Abstract]   [Full Text] [Related]  

  • 11. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
    Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
    JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of metformin treatment with enhanced effect of anti-VEGF agents in diabetic macular edema patients.
    Shao Y; Wang M; Zhu Y; Li X; Liu J
    Acta Diabetol; 2022 Apr; 59(4):553-559. PubMed ID: 35034186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal variation of optical coherence tomography biomarkers as predictors of anti-VEGF treatment outcomes in diabetic macular edema.
    Maggio E; Mete M; Sartore M; Bauci F; Guerriero M; Polito A; Pertile G
    Graefes Arch Clin Exp Ophthalmol; 2022 Mar; 260(3):807-815. PubMed ID: 34661731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation of retinal sensitivity, visual acuity and central macular thickness in different types of diabetic macular edema].
    Yang XL; Zou HD; Xu X
    Zhonghua Yan Ke Za Zhi; 2013 Dec; 49(12):1081-8. PubMed ID: 24499694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of choroidal hyperreflective foci in diabetic macular edema through a retrospective pilot study.
    Saurabh K; Roy R; Herekar S; Mistry S; Choudhari S
    Indian J Ophthalmol; 2021 Nov; 69(11):3203-3206. PubMed ID: 34708773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ranibizumab on growth factors and mediators of inflammation in the aqueous humor of patients with diabetic macular edema.
    Utsumi T; Noma H; Yasuda K; Goto H; Shimura M
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2597-2603. PubMed ID: 33772356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of monitoring vascular endothelial growth factor, monocyte chemoattractant protein-1 and Interleukin-8 in diabetic macular edema towards early identification of nonresponders to ranibizumab therapy.
    Xavier T; Pallikara S; Saji N; Radhakrishnan N; Menon KN; Pillai GS
    Indian J Ophthalmol; 2021 Jun; 69(6):1475-1481. PubMed ID: 34011723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study.
    Bonini-Filho M; Costa RA; Calucci D; Jorge R; Melo LA; Scott IU
    Am J Ophthalmol; 2009 Jun; 147(6):1022-30, 1030.e1-5. PubMed ID: 19327746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
    Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
    Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.